The National Institutes of Health has awarded a $24.4 million contract through the Rapid Acceleration of Diagnostics initiative to Greensboro, North Carolina-based Qorvo Biotechnologies, the company said on Thursday.
The contract supports the production and market launch of its Qorvo Omnia radio frequency-based diagnostic testing platform, the firm added.
The platform uses high-frequency bulk acoustic wave sensors for rapid SARS-CoV-2 antigen testing, which enable low limit of detection levels, Qorvo said.
Qorvo’s antigen test has “near-PCR-level accuracy for use at point-of-care settings,” Tiffani Bailey Lash, co-program lead for the RADx initiative, said in a statement.
Earlier this week, Qorvo Biotechnologies obtained US Food and Drug Administration Emergency Use Authorization for its COVID-19 antigen test, which runs on the Omnia platform.